1

PF04531083 - An Overview

News Discuss 
In these early clinical trials bevacizumab showed antitumor action in breast, colon, and lung cancer and identified a variety of toxicities, together with bleeding, thrombosis, hypertension, and proteinuria. The extension study was initiated in reaction to requests from patients and investigators. All patients who done ≥ one 12 months of https://haimc431kub1.wikigiogio.com/user

Comments

    No HTML

    HTML is disabled


Who Upvoted this Story